International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataDaniel A. Arber, Michael R. Savona, Lucy A. Godley et al.|Blood|2022Cited by 2.7k
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, Susan Branford et al.|Blood|2013Cited by 705
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al.|Leukemia|2012Cited by 417
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk diseaseSusan Branford, Timothy P. Hughes, Paul Wang et al.|Blood|2018Cited by 208
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2014Cited by 198